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Clauw makes several compelling points in his Commentary2 about the significance of the 
manuscript of Doppler et al.3 and the dozen others that report objective evidence of small-
fibromyalgia (SFPN) in roughly half of patients with the multi-symptom syndrome 
classically known as fibromyalgia syndrome (FMS). He rightly asserts that the association 
between FMS and SFPN is now proven, so it is time to consider its significance. This 
finding is important since fibromyalgia affects several percent of the population.23 One 
caution concerns the differences in axonal caliber between FMS and SFPN reported by 
Doppler et al.3 The medical and scientific significance of these differences is currently 
unknown, so they do not detract from the disruptive discovery of reduced intraepidermal 
nerve fiber density (IENFD) in fibromyalgia.5,9,13,14,22 A “disruptive discovery” is one that 
is ground breaking – overturning established concepts and forcing widespread changes in 
practice. As discussed by Scientific American,19 the finding of abnormal skin biopsies 
consistent with SFPN in some FMS patients is the first pathology confirmed for FMS. It 
rescues at least some FMS patients from the nonproductive “functional illness” label and 
offers new treatment possibilities. Informed FMS patients are already seeking evaluations 
for small-fiber polyneuropathy, causing bottlenecks for some neurology practices.
I hope to clarify a few misinterpretations. One is that “decreases in IENFD have been noted 
in most chronic pain conditions”.2 Actually, ENF have not yet been quantitated in most non-
neuropathic pain conditions. Clauw also suggests that reduced IENFD in “non-pain” 
disorders such as postural orthostatic tachycardia syndrome (POTS) and amyotrophic lateral 
sclerosis (ALS) invalidate the specificity of the fibromyalgia findings.2 He also makes the 
converse statement that the non-pain symptoms of fibromyalgia can’t possibly be caused by 
SFPN. These views may reflect the all-too-common unawareness of the diverse functions of 
small fibers. In fact, these unmyelinated and thinly myelinated axons innervate and modulate 
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almost every organ and tissue including the “deeper proximal structures and even visceral 
organs” that Clauw references.2 Because of the protean somatic and autonomic effects 
mediated by these omni-functional neurons, pain is only one among many symptoms of 
SFPN, and some patients with SFPN do not have chronic pain.11 And since physiologic data 
link more than 50% of POTS cases to SFPN,20 the POTS example seems invalid. 
Dysautonomic symptoms are just as characteristic of SFPN as pain. For instance, 80% of 
SFPN patients have abnormal results of sweat testing, and 75% have reduced heart-rate 
variability.21
Pathological studies also prove that small-fiber axonopathy causes abnormal innervation and 
malfunction of the body’s small blood vessels. This neurogenic microvasculopathy is a 
likely explanation for the muscle hypoperfusion, deep pain, and exercise intolerance 
characteristic not only of fibromyalgia but also of SFPN.1,4 Unexpectedly, the vascular 
dysregulation so characteristic of POTS/SFPN is able to impair higher cortical function by 
decreasing cerebral blood flow.15 These small-fiber mediated effects on the brain offer a new 
biologically plausible explanation for FMS-associated “brain fog”.18 They suggest the need 
to test whether “brain fog” in FMS patients with SFPN microvasculopathy can be treated 
using the strategies for improving brain perfusion in POTS and SFPN. These include 
expanding blood volume by augmenting salt and fluid consumption, reducing blood pooling 
in the legs with exercise and compression stockings, and treatment with midodrine or 
fludrocortisone.16
A minor disagreement is with the Commentary’s statement that there is no correlation 
between the severity of IENFD and the presence or absence of neuropathic pain.2 Although 
this is often true, my group reported a very tight correlation between the severity of loss of 
IENF and the presence or absence of postherpetic neuralgia pain after shingles.12 A 
significant correlation has also been documented in acute motor Guillain-Barré syndrome,17 
identifying another “non-pain disorder” that includes previously unappreciated neuropathic 
pain and small-fiber axonopathy.
Clauw states that there is “overwhelming evidence that the CNS is playing the major 
pathogenic role in FMS,”2 but then he confusingly attributes these changes “(usually but not 
always atrophy) in the size and shape of brain regions involved in pain processing”2 to 
secondary neuroplasticity rather than primary “encephalopathy”.2 As a neurologist, I agree 
that brain plasticity contributes to FMS symptoms, but I believe it is unlikely to have “the 
major pathogenic role”.2 Clauw himself demonstrated that changes in the brain cortex of 
fibromyalgia patients are not primary, but rather secondary to their accompanying affective 
disorders.8 Thus, these brain changes cannot be the root cause of these patients’ 
fibromyalgia. The mechanisms of the entrainment of the brain by small fibers are emerging, 
with C- and A-fibers now shown to control central pain amplification in humans.6 And in 
“classical” SFPN, the severity of small-fiber loss predicts the severity of reduced functional 
connectivity between the anterior cingulate cortex and the amygdala and precuneus.7 Many 
peripheral pain syndromes, including dysmenorrhea in normal women, also produce brain 
imaging changes,10 but surely no one believes that the brain is the primary cause of either 
SFPN or dysmenorrhea?
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Clauw correctly states that “any pain clinician will accept the use of the term SFN when an 
individual presents with classic distal neuropathic pain and has evidence of classic findings 
of decreased IENFD”2 but he downplays the new links between decreased IENFD and 
fibromyalgia. I prefer an alternate interpretation – that the signs and symptoms of SFPN are 
far broader than classically defined, and SFPN is turning out to be more common than we 
knew. The discovery that SFPN contributes to some cases of FMS offers us a chance to 
update entrenched archaic definitions of both SFPN and FMS. Disease definitions require 
regular updates to incorporate new discoveries. This benefits not only the patients, but also 
clinicians and scientists. Fibromyalgia is long overdue.
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